What if a Vaccine could be Built like Origami?

Researchers at Harvard have developed a method for folding DNA into nanoscale shapes, offering not just a new vaccine candidate, but a fundamentally different approach to how vaccines might be designed, stored, and deployed. Rather than targeting a single disease with a fixed formulation, this strategy functions as a programmable delivery platform: a structural framework that can be adapted to carry different antigens, and may be reused and modified to address multiple diseases.

A team at Harvard’s Dana-Farber Cancer Institute recently reported findings on DoriVac, a vaccine platform that uses DNA folded into precise nanoscale shapes to train the immune system. In mouse studies, it produced immune responses comparable to those of mRNA vaccines such as those developed by Pfizer and Moderna, with potential differences in storage and durability. Human trials have not yet begun.

The term “origami”  is literal

Researchers fold DNA strands into flat, square nanoparticles tens of nanometers across. One side carries immune stimulants, while the other displays fragments of a viral protein. Arranging these components approximately 3.5 nanometers apart enhanced the immune response compared to less structured delivery methods.

This organization appears to matter; a more ordered presentation of signals may allow the immune system to recognize and respond to them more effectively than when the same components are delivered without spatial control.

What the Data Shows

In mouse models across COVID-19, HIV, and Ebola, DoriVac generated both antibody responses, which block viruses from entering cells, and T-cell responses, which eliminate infected cells. In mice, immune responses persisted for up to 18 weeks after a booster dose.

Results were weaker in the HIV and Ebola models. Selecting effective antigen fragments remains a central challenge in vaccine design, and this platform does not address that problem directly.

Why it is Worth Watching

Its potential advantages are practical as well as conceptual. The platform appears stable at standard refrigerator temperatures of approximately 4°C, which, if confirmed outside laboratory conditions, could simplify storage and transport compared to more fragile vaccine technologies. Its modular design also allows different antigens to be incorporated into the same structural framework, offering flexibility across diseases without redesigning the entire system. At the same time, important uncertainties remain, particularly around manufacturing at scale, overall cost, and how the platform would perform in real-world deployment beyond controlled experimental settings.

Keep the Caveats in View

All results so far are preclinical, based on animal models and laboratory studies using human cells. These are necessary early steps, but they do not establish effectiveness in humans. No clinical trials have been announced.

The path from promising mouse data to an approved vaccine is long, expensive, and uncertain. DoriVac should be understood as an early-stage platform under investigation rather than a finished product.

The Takeaway

DoriVac illustrates an approach to vaccine design that uses nanoscale structural organization to shape immune responses. Early results in mice show that this strategy can produce both antibody and T-cell activity under controlled conditions.

Whether these findings translate to humans remains an open question. More broadly, the work highlights ongoing research into how the spatial arrangement of vaccine components may influence immune outcomes, an area which will require further study in clinical settings.

DISCLOSURE: The research team has founded DoriNano Inc. to develop this technology commercially, creating a financial interest in positive results. The study was independently peer-reviewed and published in Nature Biomedical Engineering.